Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMTM versus placebo in behavioral variant frontotemporal dementia
NL-OMON41446Phase 3Active, not recruiting
- Sponsor
- TauRx Therapeutics Ltd
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in frontotemporal dementia (FTD) comparing LMTM 200 mg/day with Placebo / low-dose LMTM colorant control (2 arms). Primary endpoints: Change from baseline to Week 52 in Addenbrooke's Cognitive Examination Revised, Change from baseline to Week 52 in Functional Activities Questionnaire and 1 more. Started May 2014; status: active, not recruiting.
02
Drugs
hydromethylthionine mesylate
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NL-OMON41446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41446.